Investigational drugs for eating disorders

Bibliography

• CROW SJ, MITCHELL JE: Integrating cognitive therapy and medications in treating bulimia nervosa. In: The Psychiatric Clinics of North America, Eating Disorders. J Yager (Ed.), WB Saunders Co., Philadelphia (1996).
   Google Scholar
• BLUNDELL JE, LAWTON CL: Mechanisms of appetite control and their abnormalities in obese patients. Horrn. Res. (1993) 39\(Suppl. 3):72–76.
   Google Scholar
• JIMERSON DC, LESEM MD, KAYE WH, BREWERTON TD: Low serotonin and dopamine metabolite concentra-tions in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch. Gen. Psychiatry (1992) 49:132–138.
   PubMed Web of Science ®Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT, JIMERSON DC,EBERT MH: CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects nor-malize after weight gain. Biol. Psychiatry (1988) 23:102–105.
   PubMed Web of Science ®Google Scholar
• KAYE WH, EBERT MH, RALEIGH M, LAKE R: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch. Gen. Psychiatry (1984) 41:350–355.
   PubMed Web of Science ®Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT, EBERT MH: Altered serotonin activity in anorexia nervosa after long-term weight restoration. Arch. Gen. Psychiatry (1991) 48:556–562.
   PubMed Web of Science ®Google Scholar
• WELTZIN TE, FERNSTROM MD, FERNSTROM JD, NEUBER-GER SK, KAYE WH: Acute tryptophane depletion and increased food intake and irritability in bulimia ner-vosa. Am. J. Psychiatry (1995) 152:1668–1671.
   PubMed Web of Science ®Google Scholar
• BREWERTON TD, MUELLER EA, LESEM MD eta].: Neuroen-docrine responses to m-chlorophenylpiperazine and L-tryptophane in bulimia. Arch. Gen. Psychiatry (1992) 49:852–861.
   Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT et al.: Elevatedcerebrospinal fluid levels of immunoreactive corticot-ropin-rele asing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J. Clin. Endocrinol Metab. (1987) 64:203.
   PubMed Web of Science ®Google Scholar
• GOLD PW, GWIRTSMAN H, AVGERINOS PC eta].: Abnor-mal hypothalamic-pituitary-adrenal function in ano-rexia nervosa. New. Engl. J. Med. (1986) 314:1335–1342.
   Google Scholar
• HOTTA M, SHIBASAKI T, MASUDA A etal: The responses of plasma adrenocorticotropic and cortisol to corticot-rophin-releasing hormone (CRID and cerebrospinal fluid immunoreactive CRH in anorexia nervosa pa-tients. J. Clin. Endocrinol. Metab. (1986) 62:319.
   PubMed Web of Science ®Google Scholar
• O'BRIEN G, HASSANYEHF, LEAKE A eta].: The dexametha-sone suppression test in bulimia nervosa. Br. J. Psychia-try (1988) 152:654–656.
   PubMed Web of Science ®Google Scholar
• WALSH BT, LO ES, COOPER T et al.: Dexamethasonesuppression test and plasma demmethasone levels in bulimia. Arch. Gen. Psychiatry (1987) 44:797–800.
   PubMed Web of Science ®Google Scholar
• MORTOLA JF, RASMUSSEN DD, YEN SSC: Alterations ofthe adrenocorticotropic-cortisol axis in normal weight bulimic women: evidence for a central mechanism. J. Clin. Endocrinol. Metab. (1989) 68:517.
   PubMed Web of Science ®Google Scholar
• BOYAR RM, HELLMAN LD, ROFFWARG HL eta].: Cortisolsecretion and metabolism in anorexia nervosa. New. Engl. J. Med. (1977) 296:190–193.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB, BREWERTON TD, FOSSEY MD et al.: CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am. J Psychiatry (1993) 150:1099–1101.
   PubMed Web of Science ®Google Scholar
• GERACIOTI TD, KLING MA, JOSEPH-VANDERPOOL JR et al.: Meal-related cholecystokinin secretion in eating and affective disorders. Psychopharmacol. Bull. (1989) 25(3)444–449.
   Google Scholar
• KAYE WH, BERRETTINI W, GWIRTSMAN H, GEORGE DT: Altered cerebrospinal fluid neuropeptide Y and pe ptide YY immunoreactivity in anorexia and bulimia nervosa. Arch. Gen. Psychiatry (1990) 47:548–556.
   PubMed Web of Science ®Google Scholar
• HUDSON JI, POPE HG, JONAS JM: Phenomenologic rela-tionship of eating disorders to major affective disorder. Psychiatry Res. (1983) 9:345–354.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, GROAT R: A placebo-controlled, double-blind trial of amitr iptyline in bulimia. J. Clin. Psychophar-macol. (1984) 4:186–193.
   PubMed Web of Science ®Google Scholar
• AGRAS WS, DORIAN B, KIRKLEY BG, ARNOW B, BACH-MAN J: Imipramine in the study of bulimia: a double-blind, controlled study. Int. J. Eating Dis. (1987) 6:29–38.
   Web of Science ®Google Scholar
• AGRAS WS, ROSSITER EM, ARNOW B eta].: Pharmacologic and cognitive-behavioural treatment for bulimia ner-vosa: a controlled clinical comparison. Am. J Psychiatry (1992) 149:82–87.
   Google Scholar
• ALGER SA, SCHWALBERG MD, BIGAOUETTE JM, MICHALEK AV, HOWARD LJ: Effect of a tricyclic antide-pressant and opiate antagonist on binge-eating behav-iour in normal-weight bulimic and obese, binge-eating subjects. Am. J. Clin. Nutr. (1991) 53:865–871.
   PubMed Web of Science ®Google Scholar
• BARLOW J, BLOUIN J, BLOUIN A, PEREZ E: Treatment of bulimia with desipramine: a double-blind, crossover study. Can. J. Psychiatry (1988) 33:129–133.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, HERZOG DB, RIVINUS TM eta].: Arnitrip-tyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J. Clin. Psychopharm-acol (1985) 5(0:10–16.
   Google Scholar
• BLOUIN AG, BLOUIN JH, PEREZ EL eta].: Treatment of bulimia with fenfluramine and desipramine. j Clin. Psychopharmacol. (1988) 8:261–269.
   Google Scholar
• FICHTER MM: Antidepressant therapy revisited for bu-limia nervosa. Proc. 9th World Congress of Psychiatry. Rio de Janiero, Brazil (1993) (Proceedings).
   Google Scholar
• FICHTER MM, LEIBL K, RIEF W eta].: Fluoxetine versus placebo: a double-blind study with bulimic in-patients undergoing intensive psychotherapy. Pharmacopsychia-try (1991) 24:1–7.
   Google Scholar
• GOLDBERG SC, HALMI KA, ECKERT ED, CASPER RC, DAVIS JM: Cyproheptadine in anorexia nervosa. Br. J. Psychiatry (1979) 134:67–70.
   PubMed Web of Science ®Google Scholar
• GOLDBLOOM D, OLMSTED M, DAVIS R, SHAW B: A randomized controlled trial of fluoxetine and individ-ual cognitive behavioural therapy for women with bulimia nervosa: short-term outcome. 6th International Conference on Eating Disorders. New York, USA (April, 1994).
   Google Scholar
• FLUOXETINE BULIMIA NERVOSA COLLABORATIVE STUDY GROUP (FBNCSG): Fluoxetine in the treatment of bulimia nervosa. Arch. Gen. Psychiatry (1992) 49:139–147.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, WILSON MG, THOMPSON VL etal: Long-term fluoxetine treatment of bulimia nervosa. Br. J. Psychiatry (Submitted).
   Google Scholar
• HORNE RL, FERGUSON JM, POPE HG eta].: Treatment ofbulimia with bup rop ion: a multicenter, controlled trial. Clin. Psychiatry (1988) 42:262–266.
   Google Scholar
• HUGHES PL, WELLS LA, CUNNINGHAM CJ, ILSTRUP DM:Treating bulimia with desipramine. Arch. Gen. Psychiatry (1986) 43:182–186.
   PubMed Web of Science ®Google Scholar
• KANERVA R, RISSANEN A: Fluoxetine in the treatment ofbulimia nervosa: psychological and behavioural changes after eight weeks' treatment. 6th International Conference on Eating Disorders. New York, USA (Arril, 1994).
   Google Scholar
• MITCHELL JE, PYLE RL, ECKERT ED eta].: A comparisonstudy of antidepressants and structured intensive group psychotherapy in the treatment of bulimia ner-vosa. Arch. Gen. Psychiatry (1990) 47:149–157.
   Google Scholar
• POPE HG, HUDSON JI, JONAS JM, YURGELUN-TODD D:Bulimia treated with imipramine: a double-blind, pla-cebo-controlled study. Am. J. Psychiatry (1983) 140:554–558.
   PubMed Web of Science ®Google Scholar
• POPE HG, HUDSON JI, JONAS JM, YURGELUN-TODD D:Antidepressant treatment of bulimia: a two year follow up study. J. Clin. Psychopharmacology (1985) 5:320–714.
   PubMed Web of Science ®Google Scholar
• POPE HG, KECK PE, MCELROY SL, HUDSON JI: A placebo-controlled study of trazodone in bulimia nervosa .J. Clin. Psychopharmacology (1989) 9:254–259.
   PubMed Web of Science ®Google Scholar
• SABINE EJ, YONACE A, FARRINGTON AJ, BARRATT KH,WAKELING A: Bulimia nervosa: a placebo-controlled double-blind therapeutic trial of mianserin. Br. J Clin. Pharmacol (1983) 15:S195–S202.
   Web of Science ®Google Scholar
• WALSH BT, GLADIS M, ROOSE SP et al.: Phenelzine vsplacebo in 50 patients with bulimia. Arch. Gen. Psychiatry (1988) 45:471–475.
   PubMed Web of Science ®Google Scholar
• WALSH BT, HADIGAN CM, DEVLIN MJ, GLADIS M, ROOSESP: Long-term outcome of antidepressant treatment for bulimia nervosa. Am. J. Psychiatry (1991) 148:1206–1212.
   PubMed Web of Science ®Google Scholar
• KIM SW, HARTMAN BK, FARIS PL etal.: Vagal involvementin the pathophysiology of bulimia nervosa: I: effect of ondansetron on binge/vomit frequencies. 7th Interna-tional Conkrence on Eating Disorders. New York, USA (1996).
   Google Scholar
• FARIS PL, HARTMAN BK, KIM SW etal.: Vagal involvementin the pathophysiology of bulimia nervosa: effect of ondansetron on binge/vomit frequencies and pain de-tection threshold. Eating Disorders Research Society Meet-ing Pittsburgh, Pennsylvania, USA (1996).
   Google Scholar
• RUSSELL GFM, CHECKLEY SA, FELDMAN J, EISLER I: Acontrolled trial of d-fenfluramine in bulimia nervosa. Clin. Neuropharmacol (1988) 11(1):S146–S159.
   PubMedGoogle Scholar
• WERMUTH BM, DAVIS KL, HOLLISTER LE, STUNKARD AJ: Phenytoin treatment of the binge eating syndrome. Am. J. Psychiatry (1977) 134:1249–1318.
   PubMed Web of Science ®Google Scholar
• HSU LKG, CLEMENT L, SANTHOUSE R, ELIM SYJ: Treat-ment of bulimia nervosa with lithium carbonate: a controlled study. J. Nerv. Ment. Dis. (1991) 179:351–355.
   PubMed Web of Science ®Google Scholar
• KRAHN D, MITCHELL JE: Use ofL-tryptophane in treating bulimia [Letter]. Am. J. Psychiatry (1985) 142:1130.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, CHRISTENSON G, JENNINGS J et al: A placebo-controlled, double-blind trial of naltrexone hydrochloride in out-patients with normal weight bu-limia. J. Clin. PFchopharmacol. (1989) 9:94–97.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, LAINE DE, MORLEY JE, LEVINE AS: Naloxone but not CCK-8 may attenuate binge-eating behaviour in patients with the bulimia syndrome. Biol. Psycho]. (1986) 21:1399–1406.
   PubMed Web of Science ®Google Scholar
• IGOIN-APFELBAUM L, APFELBAUM M: Naltrexone and bulimic symptoms [Letter]. Lancet (1987) 2(8567):1087–1088.
   PubMed Web of Science ®Google Scholar
• CROWS, MUSSELL M, PETERSON C, MITCHELL J, KNOPKE A: Adequacy of prior treatment in patients wit hbulimia nervosa. 2nd Eating Disorders Research Conference. Pitts-burgh, Pennsylvania, USA (1996).
   Google Scholar
• NIH Consensus Conference on Cost-efficacy of Psychothera-pies (1993).
   Google Scholar
• STUNKARD A, BERKOWITZ R, TANRIKUT C, REISS E, YOUNG L: d-Fenfluramine treatment of binge eating disorder. Am. J. Psychiatry (1996) 153:1455–1459.
   PubMed Web of Science ®Google Scholar
• MCCANN UD, AGRAS WS: Successful treatment of non-purging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am. J. Psychiatry (1990) 147:1509–1513.
   PubMed Web of Science ®Google Scholar
• HUDSON JE, MCELROY SL, RAYMOND NC et al.: Fluvox-amine in the treatment of binge-eating disorder: a multice nter placebo-controlled double-blind trial. Arch. Gen. Psychiatry (Submitted).
   Google Scholar
• ALGER SA, SCHWALBERG MD, BIGAOUETTE JM, MICHALEK AV, HOWARDLJ: Effect of a tricyclic antide-pressant and opiate antagonist on binge-eating behav-iour in normal-weight bulimic and obese, binge-eating subjects. Am. J. Clin. Nutt-. (1991) 53:865–871.
   PubMed Web of Science ®Google Scholar
• MARCUS MD, WING RR, EWING L eta].: A double-blind, placebo-controlled trial of fluoxetine plus behaviour modification in the treatment of obese binge-eaters and non-binge-eaters. Am. J. Psychiatry (1990) 147:876–881.
   Google Scholar
• VANDEREYCKEN W, PIERLOOT R: Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa. Acta. PsychiaTh Scand. (1982) 66:445–450.
   PubMed Web of Science ®Google Scholar
• VANDEREYCKEN W: Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulphide. Br. J. Psychiatry (1984) 144:288–292.
   PubMed Web of Science ®Google Scholar
• LACEY JH, CRISP AH: Hunger, food intake and weight:the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad. Med. (1980) 56\(Suppl. 1)79–85.
   Google Scholar
• HALMI KA, ECKERT E, LADU TJ, COHEN J: Anorexia nervosa: responses to cyproheptadine and amitrip-tyline. Arch. Gen. Psychiatry (1986) 43:177–181.
   PubMed Web of Science ®Google Scholar
• VIGERSKY RA, LORIAUX DL: The effect of cyprohep-tadine in anorexia nervosa: a double-blind trial. In: Anorexia Nervosa. RA Vigersky (Ed.), Raven Press, New York. (1977).
   Google Scholar
• STACHER G, ABUTZI-WENTZEL T-A, WIESNAGROT7KI S et al.: Gastric emptying, body weight and symptoms in primary anorexia nervosa: long-term effects of cis-apride. Br. J. Psychiatry (1993) 162:398–402.
   Google Scholar
• GROSS HA, EBERT MI-1, FADEN VB et al: A double-blind controlled trial of lithium carbonate in primary ano-rexia nervosa. J. Clin. Psychopharmacol (1981) 1(6)376–381.
   Google Scholar
• GROSS HA, EBERT MI-1, FADEN VB et al.: A double-blind trial of D9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacology (1983) 3 (3) :165–171.
   Google Scholar
• KAYE WH, MCCONAHA C, NAGATA T et al: Fluoxetine prevents relapse in a majority of patients with anorexia nervosa: a double-blind placebo-controlled study. 2nd Eating Disorders Research Conference. Pittsburgh, Pennsyl-vania, USA (1996).
   Google Scholar
• BASTIANI AM, ALTEMUS M, PIGOTT TA et al.: Comparison of obsessions and compulsions in patients with ano- rexia nervosa and obsessive compulsive disorder. Am. Psychiatry (1997) (Accepted for publication).
   Google Scholar
• PIGOTT TA, PATO MT, BERNSTEIN SE et al: Controlledcomparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry (1990) 47:926–932.
   PubMed Web of Science ®Google Scholar
• GUY-GRAND B, APFELBAUM M, CREPALDI G, GRIES A, LEFEBVRE P: International trial of long-term dexfenflu-ramine in obesity. Lancet (1989) 2:1142–1145.
   PubMed Web of Science ®Google Scholar
• ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-sup-pressant drugs and the risk of primary pulmonary hypertension. New. Engl. J. Merl. (1996) 335(9):609–16.
   PubMed Web of Science ®Google Scholar
• THULIN T, ERLINGE D: Neuropeptide Y and hyperten-sion. Nutrition (1995) 11 (Suppl. 5):495–497.
   Google Scholar
• LEIBOWITZ SF: Brain neuropeptide Y: an integrator of endocrine, metabolic and behavioural processes. Brain Res. Bull. (1991) 27:333–337.
   PubMed Web of Science ®Google Scholar